CryopPort, Inc. (OTCQB:CYRX) has developed what it believes is a "game-changing solution to the challenge of shipping biological materials" which require a frozen condition. CryoPort's offering includes CryoPort Express Shipper, a proprietary liquid nitrogen container with long holding periods and CryoPortal, a web-based ordering, tracking and monitoring system.
CryoPort's cold chain frozen shipping system targets customers in the life sciences industry which ship biological specimens such as vaccines, blood, cancer tissue and stem cells that must be kept at extremely low temperatures during transport, often over several days or even weeks, in order to prevent cell death.
Currently, the vast majority of frozen biological material is shipped using dry ice, which has a relatively short holding time...
Only subscribers can access this article, which is part of the PRO research library covering 3,592 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: